By Ben Hirschler LONDON (Reuters) – Three of Europe’s top drugmakers – GlaxoSmithKline, Roche and Sanofi – face health checks this week at high-profile presentations designed to show they can overcome looming market threats. GSK’s Andrew Witty and Sanofi’s new boss Olivier Brandicourt both need to demonstrate recovery potential, after recent disappointments, while Roche’s Severin Schwan must show he can withstand future cut-price competition to his group’s top biotech drugs. “Roche probably has the easiest job, since we know they have good data with new multiple sclerosis (MS) and oncology drugs, whereas GSK and Sanofi have quite a lot to prove,” Berenberg Bank analyst Alistair Campbell said.
Excerpt from:
Drugged up: GSK, Roche and Sanofi to set out their stalls